NDAORALPOWDERPriority Review
Approved
Jun 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
NORVIR (ritonavir) by AbbVie is hiv protease inhibitors [moa]. First approved in 2017.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORVIR (ritonavir) is an HIV protease inhibitor that blocks the protease enzyme required for HIV replication, approved in 2017. It is primarily used as a pharmacokinetic booster in combination antiretroviral regimens due to its potent CYP3A inhibition, which elevates and sustains levels of other protease inhibitors. Ritonavir enables lower doses of partner drugs while improving treatment efficacy and durability.
$0.753MPart D
PeakProduct is at peak lifecycle stage with modest Part D spending (~$753K) and low claim volume (1,933), suggesting established but limited market; marketing teams should focus on maintaining position rather than expansion.
Mechanism of Action
HIV Protease Inhibitors
Pharmacologic Class:
Cytochrome P450 3A Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns
24 enrolled
HIV InfectionsPregnancy
Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults
18 enrolled
HIV InfectionsTuberculosis
Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected Women
32 enrolled
HIV InfectionsPregnancy
Ritonavir and Indinavir in Children Failing Other Anti-HIV Treatment
29 enrolled
HIV Infections
A Study of Ritonavir/Indinavir Combination in HIV-Infected Patients
HIV Infections
Worked on NORVIR at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.